CN1486694A - Cancer treating medicine - Google Patents
Cancer treating medicine Download PDFInfo
- Publication number
- CN1486694A CN1486694A CNA031401031A CN03140103A CN1486694A CN 1486694 A CN1486694 A CN 1486694A CN A031401031 A CNA031401031 A CN A031401031A CN 03140103 A CN03140103 A CN 03140103A CN 1486694 A CN1486694 A CN 1486694A
- Authority
- CN
- China
- Prior art keywords
- total alkali
- medicine
- ethanol
- herba macleayae
- macleayae cordatae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The cancer treating medicine is prepared with bocconia cordata total alkali as material and through adding medicinal supplementary material and conventional preparation process. The bocconia cordata total alkali contains chelirubine hydrochloride over 25 wt% and sanguinarine hydrochloride over 30 wt%. The preparation process of bocconia cordata total alkali comprising three steps of ethanol extraction, acid and alkali treatment to eliminate impurity and ethanol re-crystallization to purify is also disclosed. The medicine of the present invention has high effective component content, determined treating effect, fast effect, few toxic side effect and other advantages.
Description
Affiliated technical field
The present invention relates to a kind of medicine for the treatment of cancer, being specifically related to a kind of is the Chinese patent medicine of feedstock production with the Chinese herbal medicine Herba Macleayae Cordatae.
Background technology
Herba Macleayae Cordatae Macleaya cordata (Willd) R.B[Bocconiacordata] be Papaveraceae Macleaya perennial plant, widely distributed in China, its homology plant Herba Macleayae Microcapae Macleaya microcarpa (Maxim) Fedde also does uncle and falls back to being used as medicine, medicinal its whole herb with root comprises fruit.Have parasite killing, the function of dispel the wind detoxifcation, dissipating blood stasis for subsidence of swelling, the clinical treatment of diseases such as trichomonas vaginitis, furuncle carbuncle midship, traumatic injury, rheumatic arthritis, tinea pedis, eczema, ulcer of the lower limb that are used for.Studies show that both at home and abroad Herba Macleayae Cordatae contains Sanguinarine (Sarguinarine), chelerythrine (Chelerythine), protopine (Protopine), α-allocryptopine (α-Allacryptine), bocconine multiple alkaloids such as (bocconoline).These alkaloids are the isoquinilone derivatives Alkaloid, have antibiotic, parasite killing, improve multiple pharmacological effect such as liver function, enhancing immunity, antitumor, relieving cough and asthma, analgesia.Still being difficult at present Herba Macleayae Cordatae is the Chinese medicine preparation that raw material is made the treatment cancer.
Summary of the invention
The object of the present invention is to provide a kind of is the medicine of the treatment cancer of feedstock production with the Herba Macleayae Cordatae, this effective ingredient content height, good effect, rapid-action, almost non-toxic side effect.
A kind of medicine for the treatment of cancer provided by the invention, be to be raw material with the Herba Macleayae Cordatae total alkali, add pharmaceutic adjuvant commonly used on the pharmaceutics, the medicament for preparing by the preparation common process, wherein in the Herba Macleayae Cordatae total alkali from the weight content of chelerythrine chloride hydrochlorate be higher than 25%, the weight content of Sanguinarine hydrochloride is higher than 30%.
Herba Macleayae Cordatae total alkali of the present invention prepares by following three steps:
(1) extract to concentrate: get the Chinese herbal medicine Herba Macleayae Cordatae, add the acidic ethanol reflux, extract, 1~4 time, merge extractive liquid, filters, with decompression filtrate recycling ethanol and through concentrate, leave standstill, centrifugal, it is standby to get supernatant;
(2) separate remove impurity: getting above-mentioned supernatant, is 8~10 with 20~40% sodium carbonate liquor adjust pHs, stirs evenly, leave standstill 24~48 hours, centrifugal, the collecting precipitation thing, with the methanol or the dissolve with ethanol of 6~10 times of weight of precipitate, centrifugal, branch is got supernatant, and residue is again with method dissolving 1~3 time, merge supernatant, be 3~4 with the hydrochloric acid adjust pH after, reclaim under reduced pressure is also concentrated, concentrated solution is put cold, and cold preservation was left standstill more than 18 hours, filters, the collecting precipitation thing in dry below 40 ℃, gets the total alkali crude product;
(3) crystallization purifying: get above-mentioned total alkali crude product, the ethanol that adds 10~20 times of total alkali crude product weight, 50 ℃ of heating for dissolving, filtered while hot, with decompression filtrate recycling ethanol to 1/3rd of filtrate volume, putting cold, cold preservation leaves standstill, separate out crystallization, decompress filter, leaching crystallization, in dry below 40 ℃, promptly make Herba Macleayae Cordatae total alkali of the present invention.
Used acidic ethanol is 65~85% ethanol with any adjusting pH to 3~4 in hydrochloric acid, sulphuric acid or the phosphoric acid in the above-mentioned preparation process (1).
The method for preparing the Herba Macleayae Cordatae total alkali among the present invention has method characteristics easy, with low cost, with short production cycle, is suitable for industrialized great production.The Herba Macleayae Cordatae total alkali that obtains thus can be made into the product of the acceptable any dosage form of pharmaceutics, as capsule, powder, granule, tablet, drop pill, oral liquid, freeze-dried powder or injection.Can according to circumstances add suitable adjuvant when making product, used pharmaceutic adjuvant is a kind of of acceptable any one adjuvant of pharmaceutics or several combinations.Effective ingredient content height of the present invention, determined curative effect, instant effect, dosage form be various, make things convenient for medication and transportation, almost non-toxic side effect, has bigger popularizing value.
The present invention is further illustrated below in conjunction with the specific embodiment.
The preparation of embodiment 1 Herba Macleayae Cordatae total alkali
Get 20Kg Herba Macleayae Cordatae fruit, grind, put into extraction pot, add 10 times of amounts and transfer 75% ethanol of pH to 3~4, reflux, extract, 2 times, each 1 hour with hydrochloric acid.Merge extractive liquid, filters.Filtrate is put in the concentration tank, and decompression recycling ethanol also is concentrated into relative density 1.08, leaves standstill, puts cold, centrifugal.Getting supernatant, to transfer the pH value of solution with 40% sodium carbonate liquor be 10, stirs evenly, and leaves standstill 48 hours, and centrifugal, the collecting precipitation thing is with the dissolve with ethanol of 8 times of weight of precipitate.Centrifugal, branch is got supernatant, and residue dissolves secondary with method, merges solution, and transferring the pH value of solution with hydrochloric acid is 3~4, decompression recycling ethanol, and concentrated solution leaves standstill, cold preservation 48 hours.Filter, the collecting precipitation thing in dry below 40 ℃, gets the total alkali crude product.
Above-mentioned total alkali crude product is added 15 times of amount ethanol, 50 ℃ of heating for dissolving, filtered while hot.Filtrate in 50 ℃ of decompression recycling ethanols to cumulative volume 1/3rd, placement, cold preservation 40 hours, separate out coarse-grain, decompress filter, the leaching coarse-grain, in dry below 40 ℃, macleaya cordata total alkali salt hydrochlorate 120g.Wherein contain chelerythrine hydrochloric acid 25.8%, Sanguinarine hydrochloride 31.3%.
The preparation of embodiment 2 Herba Macleayae Cordatae total alkali capsules
Get Herba Macleayae Cordatae total alkali 20g and mix with starch 200g, pulverize the back and cross 120 mesh sieves, mix homogeneously incapsulates, promptly.
The preparation of embodiment 3 Herba Macleayae Cordatae total alkali granules
Get Herba Macleayae Cordatae total alkali fine powder 10g, add dextrin 150g, mannitol 150g and soluble starch 40g, stevioside 2g, mix homogeneously is used 80% alcohol granulation, drying, and packing, promptly.
The preparation of embodiment 4 Herba Macleayae Cordatae total alkali oral liquids
Get Herba Macleayae Cordatae total alkali 10g, add 700ml distilled water and 10% hydrochloric acid solution 6ml, stirring and dissolving is filtered, and filtrate adds stevioside 1.2g and adding distil water again to 1000ml, mixing, filtration, and fill, sterilization, promptly.
The preparation of embodiment 5 Herba Macleayae Cordatae total alkali tablets
Get Herba Macleayae Cordatae total alkali fine powder 20g,, use 85% alcohol granulation with 200g starch mix homogeneously, drying, tabletting, the bag film-coat, promptly.
The preparation of embodiment 6 Herba Macleayae Cordatae total alkali injection
Get Herba Macleayae Cordatae total alkali 2.5g, polyoxyethylene sorbitan monoleate 6g, sodium chloride 9g adds injection water 800ml and 10% hydrochloric acid solution 4.5ml, and stirring and dissolving filters, and filtrate adds the injection water to 1000ml, and mixing filters with microporous filter membrane, embedding, and sterilization, promptly.
The preparation of embodiment 7 Herba Macleayae Cordatae total alkali freeze-dried powders
Get Herba Macleayae Cordatae total alkali 2g, mannitol 30g and sodium chloride 8g, add injection water 800ml and 10% hydrochloric acid solution 4ml, stirring and dissolving filters, filtrate adds the injection water to 1000ml, and mixing filters with microporous filter membrane, and filtrate is sub-packed in the sterilized cillin bottle, lyophilization, tamponade, gland, promptly.
The preparation of embodiment 8 Herba Macleayae Cordatae total alkali drop pill
Taking polyethylene glycol 4000 280g, heating and melting adds Herba Macleayae Cordatae total alkali fine powder 10g under constantly stirring, pour into behind the mixing in the drop pill machine of preheating, splashes in the refrigerative liquid paraffin with the speed of 60~80/min, takes out, and removes liquid paraffin, drying, promptly.
Pharmacodynamic test of active extract
1, Herba Macleayae Cordatae total alkali freeze-dried powder extracorporeal anti-tumor function
Adopt cultured tumor cells in vitro to measure the anti tumor activity in vitro of Herba Macleayae Cordatae total alkali lyophilized powder by the direct observation of mtt assay and cellular morphology.The experiment before with 0.9% normal saline doubling dilution in Herba Macleayae Cordatae total alkali lyophilized powder is mixed with 120.0,60.0,30.0,15.0,7.5 μ g/ml in total alkali, the medicinal liquid of drawing the above-mentioned various concentration of 10 μ L in the test adds in the 190 μ L culture medium, observe the human large intestine cancer lovo cell of Herba Macleayae Cordatae total alkali lyophilized powder to In vitro culture, people's hepatocarcinoma Hep3D cell, human bladder cancer T24 cell, the influence of mice SRS82 lymphoma cell growth, and with 5-Fu as positive control.The result shows the half-inhibition concentration (IC of Herba Macleayae Cordatae total alkali lyophilized powder to animal and human's tumor cell line
50) all below 10 μ g/ml, show that Herba Macleayae Cordatae total alkali lyophilized powder has a very strong antitumor action external; Morphology is the result show, what give Herba Macleayae Cordatae total alkali lyophilized powder respectively organizes tumor cell, and cell number descends after the administration, occurs becoming big, becomes the circle phenomenon than many cells, float in the culture medium, the prompting cell is dead, under observation finds, with the raising of dosage, cell number descends, when concentration reached certain value, large tracts of land was dead or all dead, and cell quantity has tangible dose-dependence.IC
50See the following form.
The external inhibitory action of table 1 Herba Macleayae Cordatae total alkali lyophilized powder to each group growth of cancer cells
The tumor strain | IC50 (μ g/ml) and 95% fiducial limit |
Human large intestine cancer Lovo cell | ????1.96(1.73-2.06) |
People's hepatocarcinoma Hep3D cell | ????2.46(2.13-2.76) |
Human bladder cancer T24 cell | ????3.21(2.98-3.63) |
Mice SRS82 sarcoma cell | ????3.65(3.19-4.21) |
2, Herba Macleayae Cordatae total alkali lyophilized powder anti-tumor in vivo effect
Test is adopted in the body and is moved the anti-tumor in vivo effect that tumor has been studied the Herba Macleayae Cordatae total alkali.Drug administration by injection and two kinds of route of administration of gastric infusion are adopted in test, and test dose designs as following table:
Table 2 Herba Macleayae Cordatae total alkali freeze dried powder amount design table (in total alkali)
Route of administration | The dosage group | Dosage (mg/kg) |
Drug administration by injection | High dose group | ?????12.0 |
Middle dosage group | ?????6.0 | |
Low dose group | ?????3.0 | |
Oral administration | High dose group | ?????160 |
Middle dosage group | ?????80 | |
Low dose group | ?????40 |
(1) In vitro culture mice S180 ascites tumor cell behind the inoculation kunming mice, extracts the ascites tumor cell, every mouse peritoneal injection 2.0 * 10
6Cell; Beginning in the 2nd day mouse vein administration of inoculation back or oral administration, successive administration 10 days, the life span of observing mice is calculated increase in life span.Experiment repeats twice.The results are shown in Table 3.
Table 3 Herba Macleayae Cordatae total alkali lyophilized powder is to the influence of S180 ascites tumor mice increase in life span
Route of administration | The dosage group | Dosage (mg/kg) | Tumour inhibiting rate (%) |
Drug administration by injection | High dose group | ????12.0 | ??78.6±6.85 |
Middle dosage group | ????6.0 | ??50.9±4.17 | |
Low dose group | ????3.0 | ??37.7±3.41 | |
Oral administration | High dose group | ????160 | ??66.2±5.81 |
Middle dosage group | ????80 | ??42.2±5.19 | |
Low dose group | ????40 | ??32.6±2.18 | |
Positive drug | ????5-Fu | ????20 | ??53.7±3.58 |
(2) H22 hepatoma carcinoma cell, inoculate kunming mice respectively after, extract the ascites tumor cell, every right axil subcutaneous injection 2.0 * 10 of mice
5Cell; Inoculation back administration in the 2nd day, successive administration 10 days was put to death mice on the 11st day, peeled off tumor, weighed, and calculated tumour inhibiting rate.Experiment repeats twice.The result shows and sees Table 3:
Table 4 Herba Macleayae Cordatae total alkali lyophilized powder is to the inhibitory action of H22 hepatocarcinoma
Route of administration | The dosage group | Dosage (mg/kg) | Tumour inhibiting rate (%) |
Drug administration by injection | High dose group | ????12.0 | ??63.2±4.36 |
Middle dosage group | ????6.0 | ??51.2±4.65 | |
Low dose group | ????3.0 | ??32.7±2.68 | |
Oral administration | High dose group | ????160 | ??50.8±4.18 |
Middle dosage group | ????80 | ??39.7±2.85 | |
Low dose group | ????40 | ??25.4±3.17 | |
Positive drug | ????5-Fu | ????20 | ??46.2±4.01 |
3, acute toxicity test
Give the macleaya cordata total aqueous slkali to mice by 0.2ml/10g body weight filling stomach or tail vein injection, observe general performance and the death condition of mice.The result shows, irritates the LD of stomach and drug administration by injection
50Be respectively 925.4mg/kg (886.3-968.6mg/kg) and 39.1mg/kg (34.6-43.8mg/kg).
Claims (5)
1, a kind of medicine for the treatment of cancer, it is characterized in that being is raw material with the Herba Macleayae Cordatae total alkali, add pharmaceutic adjuvant commonly used on the pharmaceutics, the medicament for preparing by the preparation common process, wherein in the Herba Macleayae Cordatae total alkali from the weight content of chelerythrine chloride hydrochlorate be higher than 25%, the weight content of Sanguinarine hydrochloride is higher than 30%.
2, the medicine of treatment cancer according to claim 1 is characterized in that described medicament is a said dosage form on any pharmaceutics.
3, the medicine of treatment cancer according to claim 2 is characterized in that described medicament is capsule, powder, granule, tablet, drop pill, oral liquid, freeze-dried powder or injection.
4, the medicine of treatment cancer according to claim 1 is characterized in that described Herba Macleayae Cordatae total alkali is to prepare by following three steps:
(1) extract to concentrate: get the Chinese herbal medicine Herba Macleayae Cordatae, add the acidic ethanol reflux, extract, 1~4 time, merge extractive liquid, filters, with decompression filtrate recycling ethanol and through concentrate, leave standstill, centrifugal, it is standby to get supernatant;
(2) separate remove impurity: getting above-mentioned supernatant, is 8~10 with 20~40% sodium carbonate liquor adjust pHs, stirs evenly, leave standstill 24~48 hours, centrifugal, the collecting precipitation thing, with the methanol or the dissolve with ethanol of 6~10 times of weight of precipitate, centrifugal, branch is got supernatant, and residue is again with method dissolving 1~3 time, merge supernatant, be 3~4 with the hydrochloric acid adjust pH after, reclaim under reduced pressure is also concentrated, concentrated solution is put cold, and cold preservation was left standstill more than 18 hours, filters, the collecting precipitation thing in dry below 40 ℃, gets the total alkali crude product;
(3) crystallization purifying: get above-mentioned total alkali crude product, the ethanol that adds 10~20 times of total alkali crude product weight, 50 ℃ of heating for dissolving, filtered while hot, with decompression filtrate recycling ethanol to 1/3rd of filtrate volume, putting cold, cold preservation leaves standstill, separate out crystallization, decompress filter, leaching crystallization, in dry below 40 ℃, promptly make Herba Macleayae Cordatae total alkali of the present invention.
5, the medicine of treatment cancer according to claim 4 is characterized in that described acidic ethanol is with any regulates 65~85% ethanol of pH to 3~4 in hydrochloric acid, sulphuric acid or the phosphoric acid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03140103 CN1217662C (en) | 2003-08-07 | 2003-08-07 | Cancer treating medicine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03140103 CN1217662C (en) | 2003-08-07 | 2003-08-07 | Cancer treating medicine |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1486694A true CN1486694A (en) | 2004-04-07 |
CN1217662C CN1217662C (en) | 2005-09-07 |
Family
ID=34155212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03140103 Expired - Fee Related CN1217662C (en) | 2003-08-07 | 2003-08-07 | Cancer treating medicine |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1217662C (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2014651A1 (en) * | 2007-07-12 | 2009-01-14 | Exonhit Therapeutics SA | Compounds and methods for modulating Rho GTPases |
EP1797427A4 (en) * | 2004-09-22 | 2009-04-08 | Odyssey Thera Inc | Methods for identifying new drug leads and new therapeutic uses for known drugs |
CN101088551B (en) * | 2006-06-13 | 2010-09-08 | 黄家曦 | Medicine for treating liver fibrosis |
CN101904849A (en) * | 2010-08-19 | 2010-12-08 | 苏州大学 | Application of sanguinarine for preparing tumour radiotherapy sensitized medicine |
WO2012079232A1 (en) * | 2010-12-15 | 2012-06-21 | Lai Hung-Cheng | Compounds used for treating cancer and the use thereof |
CN104248635A (en) * | 2013-06-27 | 2014-12-31 | 天津中医药大学 | Application of macleyine alkaloid in preparation of medicine for inhibiting P-gp |
-
2003
- 2003-08-07 CN CN 03140103 patent/CN1217662C/en not_active Expired - Fee Related
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1797427A4 (en) * | 2004-09-22 | 2009-04-08 | Odyssey Thera Inc | Methods for identifying new drug leads and new therapeutic uses for known drugs |
CN101088551B (en) * | 2006-06-13 | 2010-09-08 | 黄家曦 | Medicine for treating liver fibrosis |
EP2014651A1 (en) * | 2007-07-12 | 2009-01-14 | Exonhit Therapeutics SA | Compounds and methods for modulating Rho GTPases |
WO2009007457A3 (en) * | 2007-07-12 | 2009-03-26 | Exonhit Therapeutics Sa | Compounds and methods for modulating rho gtpases |
CN101904849A (en) * | 2010-08-19 | 2010-12-08 | 苏州大学 | Application of sanguinarine for preparing tumour radiotherapy sensitized medicine |
WO2012079232A1 (en) * | 2010-12-15 | 2012-06-21 | Lai Hung-Cheng | Compounds used for treating cancer and the use thereof |
CN104248635A (en) * | 2013-06-27 | 2014-12-31 | 天津中医药大学 | Application of macleyine alkaloid in preparation of medicine for inhibiting P-gp |
Also Published As
Publication number | Publication date |
---|---|
CN1217662C (en) | 2005-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102008475B (en) | Application of quinolizidine in preparing tumor treatment drugs | |
CN108530552B (en) | Preparation of laminarin and application of laminarin in preparation of antitumor drugs | |
CN101249259B (en) | High content and high activity oral polysaccharide-peptide and preparing method and application of the same | |
CN101904974B (en) | Chinese medicinal composition for treating malignant tumor diseases and preparation method thereof | |
CN1241574C (en) | Medicine for relieving spasm and pain and preparation process thereof | |
CN1217662C (en) | Cancer treating medicine | |
CN101747307A (en) | Glycyrrhizic acid removal glycyrrhiza flavonoid and medicament composition thereof | |
US20040067263A1 (en) | Method for preparating an anemone raddeana extract and the pharmaceutical composition containing the same as well as use thereof | |
CN1775267A (en) | Kaikoujian extract, Its preparing method and use | |
CN101411779B (en) | Chinese medicine effective component composition for treating liver cancer and method for preparing the same | |
CN101007052B (en) | An antitumor medicine and its preparation method | |
CN1931190A (en) | Toad skin extract and its medicine prepn and their prepn | |
CN102406694B (en) | Anti-tumor effective part of traditional Chinese medicine lespedeza as well as preparation method and application thereof | |
CN101125163A (en) | Plant extract and preparation with antitumor efficacy | |
CN103933100A (en) | Preparation method of total alkaloid of Chinese mahonia stem and applications of total alkaloid of Chinese mahonia stem in preparation of drugs for preventing and treating gastric ulcer | |
CN101357212B (en) | Compound cantharis injection and preparation method thereof | |
CN1247223C (en) | Greater celandine extract and its preparation method and application | |
CN101805384B (en) | Novel lycoris quinolone alkaloid and preparation method and application thereof | |
CN1257183C (en) | Clam extract, and preparing process and use thereof | |
CN101357213B (en) | Compound cantharis liquid formulation and preparation method thereof | |
CN101574381A (en) | Extractive of effective part of chloranthus glaber and preparation method thereof | |
CN110302221A (en) | The Root Bark of the Ailanthus Altissima SWINGLE total alkaloid and preparation method and application | |
CN1426783A (en) | Application of evodiamine in the preparation of medicine | |
CN102070700A (en) | Marsdenia tenacissima saponins H and preparation method and application thereof | |
CN109575089B (en) | Acylated glucose compounds, pharmaceutical composition, preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |